Cao et al. evaluated the efficacy of combination of CD19 CAR T cells with anti-PD1 antibody (nivolumab) in patients with refractory/relapsed B-cell non-Hodgkin lymphoma (Table 1). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.